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by-nc-nd/4.0/).See Clinical Research on page 213C linical trials on autosomaldominant polycystic kidney
disease (ADPKD) prove to be a
challenging endeavor because of
recruitment issues, the need for a
large sample size to evaluate efﬁ-
cacy, and the long duration of study
to prove safety, efﬁcacy, and cost.1
Adaptive trial design has been
proposed as a means to increase the
efﬁciency of randomized clinical
trials.2 Inclusion criteria for entry
into a study seems easy to handle for
established investigators until one
encounters the many patients who
prove to be ineligible because they
are “just below the margins” of
potential inclusion. Every study
seems to be hampered by study sites
that overestimate their pool of po-
tential study subjects. Then there is
a scramble to recruit the last cohort
of patients tomeet enrollment goals,
even though there can be a question
of stretching inclusion criteria.
Industry-sponsored studies are
appropriately concerned about
cost overruns, occurring often by
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Expanded eligibility criteria may
achieve the desired number of
recruitment subjects, but the power
of the study suffers by enrolling
patients who may not beneﬁt from
the proposed intervention.
Irazabal and colleagues report, in
this issue,3 the impact on the num-
ber of recruitment subjects needed
and the cost savings if prognostic
enrichment strategies were used for
the Tolvaptan TEMPO 3:4 study.
Their retrospective analysis of en-
try criteria for this study led to the
conclusion that “a speciﬁc image
classiﬁcation should be used in
randomized clinical trials to in-
crease power and reduce costs.”
Their approach is recommended for
clinical trials in ADPKD, because
results can be achieved by selecting
a group of patients with larger
height-adjusted total kidney vol-
umes (TKVs) who have exhibited
some early progression of their
disease state. In a shorter period of
time, these patients would be ex-
pected to demonstrate adverse
consequences of their PKD. There-
fore, this cohort would more likely
beneﬁt from an intervention that
proves to be successful, as illus-
trated by the statistically signiﬁcant
positive impact of the V2 receptor211antagonist on TKV, estimated
glomerular ﬁltration rate, and pain
(when analyzing data via the
enhancement approach).
Pragmatism in clinical trials arose
from concerns that many trials do
not adequately inform practice
because they are optimized to
demonstrate efﬁcacy.4 However, a
critique of “prognostic enhance-
ment” design is raised if the sample
size of highly selected participants is
reduced, as proposed in the above
classiﬁcation schemata, the potential
beneﬁt could be overestimated, and
harm underestimated. The goal of
any medication study is to deter-
mine the greatest beneﬁt /enhanced
effectiveness relative to risk.
The population studied in the
randomized Tolvaptan Tempo 3:4
study were relevant for the inter-
vention. Analysis of the selected
PKD study cohort showed charac-
teristics associatedwith amore rapid
rate of disease progression: largest
height-adjusted total kidney vol-
ume (htTKV); greater TKV slope
(percentage per year); hypertension
requiring treatment; male sex; and
increased estimated glomerular
ﬁltration rate slope of decline. The
treatment effect was most noted in
the group with the highest risk
stratiﬁcation. Investigation of the
enriched cohort is the essence of a
pragmatic trial—to inform a clinical
or policy decision by providing ev-
idence for adopting the interven-
tion. The study participantsmust be
similar to patients who would
receive the intervention if it were to
become usual care. Therefore, if the
drug is approved by the Food and
Drug Administration, the medica-
tion labeling needs to indicate
restricted use to patients who most
closely match the study cohort.
Reﬁned genotypephenotype
correlation, coupled with targe-
ted next-generation sequencing of
PKD1 and PKD2, may provide
COMMENTARY T Steinman: Prognostic Enrichment Approach in PKD Trialsuseful clinical prognostication for
ADPKD.5 The future of medication
trials may well be satisﬁed by the
“clinical trials in a dish” concept.
With increasing use of genome
sequencing as an integral aspect of
disease evaluation and potential
treatment, disease models can be
created via use of stem cell tech-
nology, as has been accomplished in
PKD.6 Divided cell cultures will
allow treated and control lines that
are perfectly matched. The medi-
cation being studied can be added
to the cultured cells at different
doses. Proof of principle, or lack
thereof, can be detected in a rela-
tively short period of time. Patient
trials, if justiﬁed, can then proceed
in a more focused approach. Hence,
pragmatic trial principles will allow
for shorter-length studies in a212well-deﬁned population. Reduced
costs of trialswill encouragemore of
them. With the recent direct isola-
tion and characterization of human
nephron progenitors, this in vitro
system facilitates studies of human
renal development and can be a
novel future tool for bioengineering
purposes.7 Until this approach
comes to fruition, the prognostic
enhancement study design will be a
positive step forward.
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